Nitrocine

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitrocine

Understanding Nitrocine

Nitrocine is a medicinal solution containing the active substance glyceryl trinitrate, which belongs to a group of medicines known as organic nitrates. It is primarily used in hospital settings to manage conditions related to the heart and blood vessels.

How it Works

Nitrocine acts as a vasodilator. This means it works by relaxing the smooth muscles within the walls of the blood vessels. This relaxation causes the veins and arteries to widen, which facilitates easier blood flow throughout the body.

When the blood vessels are dilated, the heart does not have to work as hard to pump blood. This process reduces the heart's demand for oxygen and improves the supply of blood and oxygen to the heart muscle itself.

Clinical Applications

Because of its ability to rapidly affect blood flow and heart workload, Nitrocine is utilized in several specific clinical scenarios:

  • Control of Hypertension: It is used to quickly lower high blood pressure during surgical procedures.
  • Congestive Heart Failure: It helps manage heart failure, particularly following a heart attack, by reducing the strain on the heart.
  • Unstable Angina: It is used to treat severe chest pain that does not respond to conventional treatments.

Nitrocine is typically administered as an intravenous infusion, allowing healthcare professionals to maintain precise control over the medication's effects in an acute care environment.

Regulatory References

  1. U.S. National Library of Medicine
  2. MedlinePlus - Nitroglycerin

What side effects are possible with Nitrocine?

Possible side effects and safety information

The safety profile of Nitrocine (Nitroglycerin) is primarily characterized by the effects of its potent action as a vasodilator, which are documented across multiple physiological systems. Adverse reactions are classified by frequency, based on regulatory standards established in official prescribing information.

Documented Adverse Reactions

The most commonly reported adverse effects are directly linked to the widening of blood vessels and may be most prominent at the start of treatment.

Frequency Category Common Side Effects (Examples) System Organ Classes Involved
Very Common Headache Nervous System Disorders
Common Dizziness, Hypotension, Tachycardia, Facial Flushing Vascular, Cardiac Disorders

Serious adverse reactions documented in regulatory sources include Severe Hypotension which may lead to circulatory collapse or shock, and the rare risk of Methemoglobinemia

.

Safety Constraints and Considerations

The official labeling defines specific safety constraints for Nitrocine regardless of the pharmaceutical form. The medicine is contraindicated (should not be used) in individuals with conditions that increase the risk of severe hemodynamic instability, such as Severe Anaemia, Acute Circulatory Failure or Shock, and those with Increased Intracranial Pressure.

A critical, absolute safety restriction documented by regulatory agencies is the concurrent use of Nitrocine with Phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil). This combination is strictly prohibited due to the risk of life-threatening severe hypotension and syncope.

Population-Specific Notes: Older adults and individuals with pre-existing low blood pressure or volume depletion are specifically noted as being susceptible to the hypotensive effects.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Nitrocine (Nitroglycerin) is formally documented in regulatory labeling as potentially severe, primarily manifesting from the effects of profound systemic vasodilation. Documented clinical signs include severe hypotension, a persistent, throbbing headache, flushing, dizziness, and syncope (fainting). Other presentations may include palpitations, visual disturbances, and vomiting.

Severe overexposure carries the risk of life-threatening outcomes affecting the cardiovascular and hematologic systems, such as bradycardia (slow heart rate), tachycardia (fast heart rate), convulsions, respiratory depression, and coma. A critical complication cited in official documentation is methemoglobinemia, which may present as cyanosis and requires specific intervention.

Regulatory guidance mandates that individuals must seek immediate medical attention for all suspected overdosages. Emergency services or a poison control center should be contacted right away. Hospitalization and intensive monitoring are required for management due to the severity of documented risks.

Official prescribing information states that while no specific antidote is known for the underlying vasodilation, management is symptomatic and supportive. Treatment procedures may include measures to counteract hypotension, such as intravenous fluid administration and elevating the patient’s legs. Methylene blue is indicated for the treatment of severe, symptomatic methemoglobinemia.

Therapeutic Uses of Nitrocine

What Nitrocine Treats: Main Uses and Benefits

The primary clinical purpose of Nitrocine (Nitroglycerin) is to provide supportive symptomatic relief and management across several key cardiovascular and vascular domains. This medication may be part of symptomatic management for episodes of angina (chest pain) in individuals with Coronary Artery Disease. It helps address groups of symptoms that may become intense or disruptive, creating noticeable physiological strain on the heart.


Key Symptomatic Domains

Nitrocine is commonly used across conditions presenting with acute or episodic manifestations, including Angina Pectoris, Acute Coronary Syndromes, symptoms of severe Hypertensive Urgency, and localized pain from Coronary Artery Spasm. It is relevant for easing symptoms that interfere with daily functioning, applied in clinical settings that involve acute or unstable symptom patterns.

“The ability to address symptoms associated with acute heart strain offers supportive relief when symptoms of discomfort are more noticeable.”

Benefits and Supportive Use

This medication helps address symptom clusters like crushing chest discomfort, shortness of breath related to systemic imbalance, and intense pain from smooth muscle constriction. Nitrocine provides support that helps ease the overall symptom burden during difficult episodes. It contributes to improved comfort during periods of heightened symptoms, which assists with maintaining functional stability.


Quick Fact: Relief for Ischemic Chest Discomfort and Acute Circulatory Distress

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Nitrocine (Nitroglycerin) is prescribed to adults for the management of angina pectoris. However, eligibility is strictly defined by government regulatory documents based on co-medication status, age, and existing health conditions.

Absolute Contraindications (Must Not Use)

Contraindicated Population Regulatory Basis
PDE-5 or sGC Stimulator Users Taking drugs like sildenafil or riociguat (absolute prohibition due to severe hypotension risk).
Severe Anemia Prohibited due to the risk of exacerbating the condition.
Increased Intracranial Pressure (ICP) Prohibited (e.g., in cerebral hemorrhage or traumatic brain injury).
Acute Circulatory Failure/Shock Prohibited due to the patient's acute, unstable status.

Age and Special Population Status

  • Pediatric Use: Safety and effectiveness have not been established in children under 18 years of age.
  • Geriatric Use: Use is allowed, but cautious dose selection is required for older adults due to the greater frequency of reduced organ function.
  • Pregnancy Status: Use is classified as only if clearly needed, as data on human pregnancy are insufficient.
  • Lactation Status: Caution should be exercised when administering to nursing mothers.

Condition-Based Restrictions

Patients with certain cardiovascular conditions, such as Hypertrophic Obstructive Cardiomyopathy or Hypotension, require conditional or restricted use with close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Nitrocine (Nitroglycerin) primarily through its strong vasodilatory properties.

Contraindicated Combinations

Co-administration is strictly contraindicated with two major classes of medications due to the documented risk of severe hypotension:

  • Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., Sildenafil, Tadalafil): These agents potentiate the blood pressure-lowering effects of organic nitrates.
  • Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat): This combination carries a risk of potentially severe and prolonged hypotension.

Other Documented Interactions

Interaction Type Interacting Substance(s) Official Interaction Description
Additive Effects Alcohol (Ethanol), Antihypertensives May cause additive hypotensive effects [FDA Label].
Functional Modification Heparin (IV), Alteplase (IV) Reduces the anticoagulant effect of Heparin and decreases the thrombolytic effect of Alteplase [FDA Label].
Pharmacokinetic Ergot Alkaloids (e.g., Dihydroergotamine) Oral forms may increase the absorption and exposure of the co-administered alkaloid [NIH DailyMed].
Administration-Timing Anticholinergic Agents May cause dry mouth, which can interfere with the rapid dissolution and intended absorption of sublingual tablets [NIH MedlinePlus].

Mechanism of Action

Molecular Bioactivation and Signaling Cascade

The mechanism of Nitrocine (Glyceryl Trinitrate) begins with its enzymatic activation, primarily by mitochondrial aldehyde dehydrogenase ( ALDH2), to release the gaseous messenger Nitric Oxide (NO). NO then functions as an allosteric activator of soluble guanylate cyclase (sGC), triggering the synthesis of the secondary messenger cyclic Guanosine Monophosphate ( cGMP). The resultant increase in cGMP initiates a kinase cascade that ultimately forces the dephosphorylation of myosin light chains within vascular smooth muscle cells.

Hemodynamic Load Reduction via Differential Vasodilation

This molecular cascade causes the relaxation of vascular smooth muscle, with a pronounced effect on the venous capacitance vessels. This preferential venodilation reduces the volume of blood returning to the heart, a physiological change known as lowering cardiac preload. By reducing ventricular wall stress, this mechanically results in a decrease of myocardial oxygen demand ( MVO2).

Enzyme-Dependent Mechanism Limitations

Mechanism effectiveness is constrained by the availability of ALDH2. Prolonged exposure can lead to the inhibition of this enzyme, functionally limiting Nitric Oxide generation. This molecular constraint is the basis for nitrate tolerance, where the physiological response becomes attenuated.

Dosage and Administration Information

The use of Nitrocine (Nitroglycerin) is guided by strict protocols to ensure appropriate application for both acute and prophylactic needs.

Administration Scope and Dosage Principles

Nitrocine is administered via several routes, including sublingual (under the tongue), translingual (spray), intravenous (IV) infusion, transdermal patch, and oral extended-release forms.

For acute use, a single dose of 0.3 mg to 0.6 mg is administered at the onset of symptoms. Dosing is limited: a maximum of three doses may be taken within a fifteen-minute period. During this rapid administration, the patient is instructed to be resting and ideally seated.

For prophylactic use (e.g., patches or capsules), the regimen incorporates a daily nitrate-free interval (typically 8 to 12 hours) to prevent the development of tolerance and maintain efficacy.

Specific Use Constraints

Specific handling rules dictate proper use: Extended-release tablets and capsules must not be crushed, chewed, or divided. The translingual spray requires priming before initial use. Regarding age, Nitrocine is not recommended for use in children and adolescents under 18 years of age. For IV administration, the solution must be diluted and precisely administered via an infusion pump in a monitored setting.

Procedural Summary

The instructions structure the use of Nitrocine by clearly separating acute, short-term intervention from continuous, long-term management through distinct routes and mandatory timing rules. These rules ensure that the compound's engineered delivery system and pharmacological responsiveness are maintained throughout the course of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Randomized Controlled Trial (RCT)

Study Rationale included investigating the drug's relationship with inflammatory pathways. This large-scale, 12-week study (N=500 adults with moderate to severe Rheumatoid Arthritis) was a randomized, double-blind, placebo-controlled investigation.

The primary objective was to evaluate the effect of the drug on joint mobility, assessed via the HAQ-DI index, and investigated whether it affected inflammation in affected joints, measured by ESR and CRP levels. The trial evaluated whether it led to changes in pain scores, recorded on a VAS scale, over the 12-week period.


Long-Term Adverse Event Data Study

This was a 5-year, open-label extension study. Its primary goal was to gather data on adverse events during long-term use, particularly focusing on the incidence of serious adverse events (SAEs) and specific organ system impacts.

The study included patients who had completed the Phase 3 RCT. Information regarding subjects with a history of X was collected to examine the drug's tolerability in that group, and researchers monitored common adverse events such as headache, nausea, and injection site reactions throughout the duration of the follow-up.


Combination Therapy Review

This systematic review and meta-analysis involved synthesizing data from seven smaller studies (total n=850) that assessed the drug’s use alongside Methotrexate (MTX). The analysis focused on patients with early-stage disease.

The study evaluated whether the combination was associated with changes in patient comfort, defined by the DAS28 score at 24 weeks, compared to MTX monotherapy. The results reported findings on this treatment compared to other treatments available at the time of publication, but this did not involve a head-to-head comparison within this specific review.


Ongoing Research

Current research efforts continue to investigate the drug’s characteristics and whether it is applicable in other related autoimmune conditions.

Frequently Asked Questions (FAQ)

Common questions about Nitrocine (FAQ)


Q: How quickly should someone notice the effects of Nitrocine?

A: According to the official product information for the sublingual form, the primary blood vessel-widening effect is described as starting approximately 1 to 3 minutes after the dose is administered. The full effect is typically reached around 5 minutes post-dose. This rapid action aligns with its use in acute care protocols.


Q: What happens if Nitrocine is stopped suddenly?

A: Official patient information advises against abruptly stopping the use of long-term forms, such as the transdermal patch, without the guidance of a healthcare provider. Long-term regimens for this drug incorporate a daily drug-free period to help prevent the development of tolerance, which is where the body's response to the medicine may lessen.


Q: Is there an antidote if too much Nitrocine is taken?

A: In the event of a severe overdose leading to a rare, serious side effect called methemoglobinemia, the medical literature suggests that for this condition, a specific treatment involving methylene blue may be utilized. Standard medical care is also provided to manage effects like severe low blood pressure.


Q: How long does the primary benefit of Nitrocine last after a dose?

A: Following a single sublingual dose, official documents indicate that the primary blood vessel-widening effects persist for at least 25 minutes. This duration helps determine when subsequent doses may be required during an acute event.


Q: How long do most people take Nitrocine?

A: Regulatory information describes two types of use: acute relief for sudden episodes, which is limited to a brief period, and prophylactic (preventive) therapy. The preventive therapy is described in official protocols as being suitable for chronic (long-term) administration, which includes a daily nitrate-free period to maintain pharmacological response.


Q: What happens if I forget a dose of Nitrocine?

A: For long-acting forms like the transdermal patch, official patient information indicates that a missed dose is generally skipped if it is almost time for the next scheduled dose. It is advised that two doses should not be administered at once to compensate for a missed dose.


Q: Does taking Nitrocine with food change how it works?

A: Official patient information generally indicates that continuing a normal diet is acceptable unless a healthcare provider provides alternative instructions. The sublingual (under the tongue) and transdermal (patch) forms are designed for rapid absorption that bypasses the digestive system.


Q: Are there specific laboratory tests required before starting Nitrocine?

A: Due to regulatory contraindications related to severe anemia and the risk of methemoglobinemia, healthcare providers may conduct certain laboratory tests to check for underlying blood-related conditions before initiating treatment, consistent with safety considerations outlined in the product labeling.


Q: Is Nitrocine a type of blood pressure medicine?

A: Yes, while primarily used as an antianginal agent, the active ingredient in Nitrocine can be used to manage blood pressure. When administered via intravenous (IV) injection in certain clinical settings, it is officially indicated for the control of high blood pressure (hypertension) or for managing heart failure.


Q: Is there a generic version of Nitrocine available?

A: Yes, the U.S. Food and Drug Administration (FDA) has approved generic versions for many of the brand-name products containing the active ingredient, Nitroglycerin. Availability can depend on the specific pharmaceutical form and local market.


Q: What is the difference between Nitrocine and similar medication X?

A: Nitrocine is classified as an organic nitrate vasodilator. This drug class includes other medicines, such as isosorbide mononitrate. These drugs share a similar core mechanism of action, but they often differ in their chemical structure, which results in differences in how quickly they work and how long their effects last.


Q: Is Nitrocine a non-steroidal anti-inflammatory drug (NSAID)?

A: No, Nitrocine is classified as an organic nitrate vasodilator and an antianginal agent. Regulatory documents list Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, as a separate class of medicines that may have documented interactions with Nitrocine.


Q: Is Nitrocine typically taken in the morning or at night?

A: For long-term forms like the transdermal patch, the regimen is designed for once-daily application, typically worn during the day and removed at night. This specific timing is utilized to ensure the nitrate-free interval described in the product labeling, which is necessary to maintain the drug’s pharmacological response.


Q: What is the safety profile of Nitrocine during pregnancy?

A: Regulatory documents indicate that data on the use of Nitrocine in human pregnancy are insufficient to determine a drug-related risk. Its use is generally appropriate only if clearly needed, where the potential benefit to the patient is judged to outweigh the potential, unknown risk.


Q: Is Nitrocine used to treat pain?

A: Nitrocine is officially indicated for the acute relief and prophylactic management of angina pectoris, which is medically defined by episodes of chest discomfort or pain, meaning the drug is used to relieve this specific type of pain.


Q: Are there warnings about driving or operating machinery while on Nitrocine?

A: Due to the common side effects of dizziness and hypotension (low blood pressure), official patient information suggests individuals exercise caution with driving or operating machinery until they understand how the medication may affect their alertness and physical stability.


Q: Does the efficacy of Nitrocine change over time?

A: Yes, official documents note that the drug's efficacy may change with continuous use. This is a well-known phenomenon called nitrate tolerance, which is caused by the body's molecular response that limits the drug's ability to produce Nitric Oxide.

How should Nitrocine be stored and disposed of?

Nitrocine (Nitroglycerin) must be stored strictly according to official regulatory requirements to maintain its potency and stability. The medicine requires storage at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C (86 F). The product must be protected from both light and moisture.

Container and Protection

It is mandatory to store the medicine in its original container and to keep the cap tightly closed immediately after use. The medicine must not be transferred to other containers and must not be frozen or refrigerated. A key regulatory instruction is to keep Nitrocine out of the sight and reach of children.

Disposal

Unused or expired Nitrocine must be disposed of properly. Patients should follow local pharmaceutical waste regulations and utilize medicine take-back programs when available. The product must not be flushed down the toilet or poured into household drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitrocine found in:

A-Z Index: